Abstract
Glioblastoma is the most common astrocytic brain tumor in humans. Current therapies for this malignancy are mostly ineffective. Photodynamic therapy (PDT), an exciting treatment strategy based on activation of a photosensitizer, has not yet been extensively explored for treating glioblastoma. We used 5-aminolevulinic acid (5-ALA) as a photosensitizer for PDT to induce apoptosis in human malignant glioblastoma U87MG cells and to understand the underlying molecular mechanisms. Trypan blue dye exclusion test showed a decrease in cell viability after exposure to increasing doses of 5-ALA for 4h followed by PDT with a broad spectrum blue light (400-550 nm) at a dose of 18J/cm(2) for 1h and then incubation at 37 degrees C for 4h. Following 0.5 and 1mM 5-ALA-based PDT (5-ALA-PDT), Wright staining and ApopTag assay showed occurrence of apoptosis morphologically and biochemically, respectively. After 5-ALA-PDT, down regulation of nuclear factor kappa B (NFkappaB) and baculovirus inhibitor-of-apoptosis repeat containing-3 (BIRC-3) protein indicated inhibition of survival signals. Besides, 5-ALA-PDT caused increase in Bax:Bcl-2 ratio and mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF). Activation of calpain, caspase-9, and caspase-3 occurred in course of apoptosis. Calpain and caspase-3 activities cleaved alpha-spectrin at specific sites generating 145kD spectrin breakdown product (SBDP) and 120kD SBDP, respectively. The results suggested that 5-ALA-PDT induced apoptosis in U87MG cells by suppression of survival signals and activation of proteolytic pathways. Thus, 5-ALA-PDT can be an effective strategy for inducing apoptosis in glioblastoma.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminolevulinic Acid / chemistry
-
Aminolevulinic Acid / pharmacology*
-
Aminolevulinic Acid / therapeutic use
-
Apoptosis / drug effects*
-
Apoptosis / physiology
-
Apoptosis / radiation effects
-
Apoptosis Inducing Factor / drug effects
-
Apoptosis Inducing Factor / metabolism
-
Apoptosis Inducing Factor / radiation effects
-
Apoptosis Regulatory Proteins / antagonists & inhibitors
-
Apoptosis Regulatory Proteins / metabolism
-
Apoptosis Regulatory Proteins / radiation effects
-
Baculoviral IAP Repeat-Containing 3 Protein
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / metabolism
-
Brain Neoplasms / physiopathology
-
Calpain / drug effects
-
Calpain / metabolism
-
Calpain / radiation effects
-
Caspases / drug effects
-
Caspases / metabolism
-
Caspases / radiation effects
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cell Survival / physiology
-
Cell Survival / radiation effects
-
Dose-Response Relationship, Drug
-
Glioblastoma / drug therapy*
-
Glioblastoma / metabolism
-
Glioblastoma / physiopathology
-
Humans
-
Inhibitor of Apoptosis Proteins / drug effects
-
Inhibitor of Apoptosis Proteins / metabolism
-
Inhibitor of Apoptosis Proteins / radiation effects
-
NF-kappa B / drug effects
-
NF-kappa B / metabolism
-
NF-kappa B / radiation effects
-
Peptide Hydrolases / drug effects*
-
Peptide Hydrolases / metabolism
-
Peptide Hydrolases / radiation effects
-
Photochemotherapy / methods*
-
Ubiquitin-Protein Ligases
Substances
-
Apoptosis Inducing Factor
-
Apoptosis Regulatory Proteins
-
Inhibitor of Apoptosis Proteins
-
NF-kappa B
-
Aminolevulinic Acid
-
BIRC3 protein, human
-
Baculoviral IAP Repeat-Containing 3 Protein
-
Ubiquitin-Protein Ligases
-
Peptide Hydrolases
-
Calpain
-
Caspases